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Abstract. As the global COVID-19 pandemic continues, unabated and clinical trials demonstrate limited effective
pharmaceutical interventions, there is a pressing need to accelerate treatment evaluations. Among options for
accelerateddevelopment is the evaluation of drug combinations in the absence of priormonotherapy data. This approach
is appealing for a number of reasons. First, combining two or more drugs with related or complementary therapeutic
effects permits a multipronged approach addressing the variable pathways of the disease. Second, if an individual
component of a combination offers a therapeutic effect, then in the absence of antagonism, a trial of combination therapy
should still detect individual efficacy. Third, this strategy is time saving. Rather than taking a stepwise approach to
evaluating monotherapies, this strategy begins with testing all relevant therapeutic options. Finally, given the severity of
the current pandemic and the absence of treatment options, the likelihood of detecting a treatment effect with combi-
nation therapymaintains scientific enthusiasm for evaluating repurposed treatments. Antiviral combination selection can
be facilitated by insights regarding SARS-CoV-2 pathophysiology and cell cycle dynamics, supported by infectious
disease and clinical pharmacology expert advice. We describe a clinical evaluation strategy using adaptive combination
platform trials to rapidly test combination therapies to treat COVID-19.
For novel COVID-19, there has been extensive focus on
repurposing previously approved drugs against SARS-CoV-
2.1 Repurposing is attractive, as it allows the use of existing
information on human pharmacology and clinical safety to
enable faster clinical trial development and rollout.2 In addi-
tion, repurposing drugs offers the potential to rapidly and ef-
ficiently scale effective treatments, in contrast to newer
therapies that require upscaling drug manufacturing and
supply chain pathways.
To illustrate, a recent large-scale compound repurposing
effort identified more than 20 antivirals that should be further
investigated for application for COVID-19.3 Antiviral agents for
COVID-19 can be categorized by two broad mechanisms of
action: 1) those targeting viral proteins or nucleic acids related
to infection of host cells, viral production via hijacking cellular
machinery, or release fromhost cells and circulation of virions;
and 2) those targeting essential host functions for viral repli-
cation including agents such as interferon that boost the cel-
lular immune response to infection. Each category is complex,
andof the armament of potential repurposeddrugs forCOVID-
19, multitudes of mechanisms and pathways are in consid-
eration. Selectively combining agents to complement each
other by variable mechanisms of action across these cate-
gories may yield effective treatments for select phases of
SARS-CoV-2 infection. Analogous to the evolution of anti-
retroviral therapies forHIV infection, it is important to formulate
and test combination therapy regimens. Instead of sequen-
tially testingmonotherapies thatwill likely havemodest clinical
effects on their own, additive or synergistic effects can po-
tentially be gained by combining antiviral drugs exploiting
pharmacology throughout the spectrumof COVID-19 illness.4
There are more than 750 clinical trials evaluating repur-
posed therapies for COVID-19.1 These trials cover all antiviral
mechanisms noted earlier and applications from prophylaxis
to treatment to reduction in the sequelae of the host in-
flammatory response. However, to date, only dexamethasone
and remdesivir have been identified as effective therapies for
severely ill patients.5,6 This low success rate might be due to
the fact that the majority of COVID-19 clinical trials (87%) are
evaluating repurposed drugs as monotherapy.1
Combination therapies for COVID-19 represent an attrac-
tive approach to drug development. Among the first trials
published of effective interventions for COVID-19 was a
combination of interferon beta-1b, lopinavir–ritonavir (LPV/r),
and ribavirin for hospitalized patients.7 In comparison to the
control group that received LPV/r monotherapy, the triple
combination arm showed faster viral clearance and alleviation
of symptoms, and shorter hospital stays.7 Although LPV/r
monotherapy was no better than placebo alone in another
hospitalized trial (RECOVERY),8 it is unclear whether both in-
terferon beta-1b and ribavirin or triple combination therapy
drove clinical benefits for hospitalized patients.
ESTABLISHING COMBINATION THERAPIES
Under normal circumstances, development of combination
treatmentstrategiesentailsastepwiseevaluationprocesswhereby
first the individual components of a potential combination regimen
are tested forclinical efficacy in isolationoras individual armswithin
a trial evaluating both single and combination regimens. This
strategy allows sequential compilation of evidence for each drug
before studying combinations, as outlined by the U.S. Food and
Drug Administration in describing the so-called combination rule.9
This process is basedon reducing exposure to ineffective or
toxic drugs among participants until individual components
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have demonstrated treatment effects. Although this process
isboth scientifically rigorous andsafe, it is slow, andmaydelay
identification of unexpected synergistic effects, resulting in
failure to evaluate potentially potent treatment cocktails.
ACCELERATING COMBINATION THERAPIES
As the global pandemic continues, unabated and thera-
peutic options evaluated to date demonstrate limited effec-
tiveness, and there is a pressing need to accelerate treatment
evaluations. Among the options for accelerated development
is the evaluation of combination strategies in the absence
of prior monotherapy data. This approach is appealing for
a number of reasons. First, combining two or more drugs
with complementary antiviral or therapeutic effects permits a
multipronged approach addressing the variable pathways of
the disease. Second, if an individual component of a combi-
nation strategy offers a therapeutic effect, then the clinical trial
should still detect treatment effects unless antagonism be-
tween components is present. Third, this strategy saves time,
as it accelerates evaluation of prioritized combination regi-
mensmuch earlier thanwould occurwith a stepwise approach
evaluatingmonotherapies before combinations. Finally, given
the severity of the current pandemic, and the current absence
of verified treatment options, the likelihood of detecting a
treatment effect with combination therapymaintains scientific
and patient enthusiasm for repurposed treatments.
Despite these advantages, there has been limited research
activity investigating combination therapy for COVID-19, in
clear contrast to other disease areas. Among the 1971 regis-
tered clinical trials evaluating all therapeutic interventions (i.e.,
not only previously approved treatments) for COVID-19,1 only
258 (13.1%) trials are evaluating combination therapies. Of
these, 120 trials are taking a stepwise approach, and 138 trials
are evaluating combination strategies without associated in-
dividual monotherapies. Determining whether these trials are
implementing a forward (evaluating monotherapy before
combination therapy) or backward stepwise approach is not
possible from clinical trial registries.
TRIAL DESIGN FOR EVALUATING COMBINATIONS AND
THEIR COMPONENTS
Among the many scientific lessons of the COVID-19 pan-
demic has been the widespread embrace of adaptive clinical
trials, particularly platform trials inwhichmultiple interventions
are compared simultaneously against a common control arm,
and in which interventions may be added over time.10,11
FIGURE 1. A platform trial for combination therapy. Here, in this example, there are several interim analyses planned for the platform trial testing
combination therapies using a backward stepwise approach. At the first interim analysis, combination arm 1 is dropped for futility followed by
combination arm 2 dropped at the second interim analysis. At the third interim analysis, combination arm 3 shows superiority over placebo (PBO),
and, thereafter, individual monotherapies are added and evaluated after.
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Although this concept is not new, it has historically been
controversial and limited to industry-run clinical trials, espe-
cially in oncology. In adaptive clinical trial designs, pre-
specified modifications are permitted with decision rules
based on accumulated interim data.12 Adaptive designs have
been controversial because interim data are often assessed
multiple times, leading to a fear of inflated type I error rates.
However, statistical measures can be implemented to control
the type I error rate at the usual 5%. Important examples of
adaptive platform trials directed toward COVID-19 include the
RECOVERY,5 SOLIDARITY,13 and REMAP-CAP14 trials.
Adaptive platform trials provide capacity in combination
trials to add or remove ineffective treatment arms, allowing for
sequential comparisons and a perpetual design wherein treat-
ments can be prioritized or de-prioritized as evidence accumu-
lates. We propose a platform trial to evaluate combination
therapies in theabsenceofmonotherapyevaluations (Figure1). If
the combination is ineffective, then there is reduced incentive to
evaluate the monotherapies. If the combination demonstrates
efficacy, then monotherapy arms can be studied to determine
which components of the combination therapy are efficacious.
Our proposed approach is not without limitations. Evaluat-
ing combinations assumes that individual components are
nonantagonistic and likely either additive or synergistic. There
are important examples of drug therapies that exhibit
antagonism.15,16 Thus, combination strategies may miss ef-
ficacy of individual components undermined by antagonism.
Furthermore, drug interactions may result in adverse events
and toxicity notobservedwithmonotherapy. Therefore, it is critical
to engage clinical pharmacologists and infectious disease experts
in guiding the selection and refinement of regimens to ensure that
insightsonSARS-CoV-2pathophysiology, cell cycle dynamics,
mechanisms of action, drug–drug interactions, safety sig-
nals, and clinical utility are appropriately incorporated in the
selection of combinations for study.
Ultimately, we argue that the best approach to quickly es-
tablish efficacy of potential therapies for COVID-19 is through
studying combination therapies, ideally with demonstrated in vitro
and in vivo activities and strong preclinical properties, in an
adaptive framework tomaximize theprobability of clinical efficacy.
This strategy challenges the traditional drug development dogma,
but we believe that it will accelerate the development of repur-
posed drugs as combination therapies to treat COVID-19.
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